A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination With Ribavirin in Treatment-Relapsed and Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection

Trial Profile

A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination With Ribavirin in Treatment-Relapsed and Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Peginterferon lambda-1a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors ZymoGenetics
  • Most Recent Events

    • 09 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Oct 2009 Results will be presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), held in Boston, Massachusetts from 30 Oct 2009 to 3 Nov 2009.
    • 26 Aug 2009 Planned end date changed from 1 Jun 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top